Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 54, 5636-5642, November 1, 1994]
© 1994 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knight, G. D.
Right arrow Articles by Scallen, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knight, G. D.
Right arrow Articles by Scallen, T. J.

Seemingly Diverse Activities of ß-Alethine1

Galen D. Knight, Paul L. Mann, Kevin H. Laubscher and Terence J. Scallen2

School of Medicine [G. D. K., K. H. L., T. J. S.], and College of Pharmacy [P. L. M.], University of New Mexico, Albuquerque, New Mexico 87131

ß-Alethine (ß-alanyl-cysteamine disulfide) exhibits striking biological activities in diverse systems. At an optimum of about 10 ng/ml, ß-alethine (a) adapts murine liver cells to culture (53 colonies/106 cells versus none in controls), (b) delays aging of human IMR-90 fetal lung fibroblasts (102 population doubling levels versus 47 in controls, producing 3 x 1016 greater biomass), and (c) markedly stimulates antibody-producing plaque-forming cells from murine splenocytes (16,875/106 cells versus 55/106 cells in controls) or human peripheral blood leukocytes (1826/106 cells versus 0/106 cells in controls). Early interventions with ß-alethine (1 ng/kg to 100 µg/kg) successfully treat NS-1 myeloma in a syngeneic murine tumor model (NS-1 myeloma). Although there are indications in this model that ß-alethine is also effective when intervention is late, ß-alethine is ineffective in an allogeneic murine melanoma model (Cloudman S-91 melanoma). It is inferred that ß-alethine enhances cellular phenotypic expression, function, and vitality in diverse biological systems and may treat certain types of neoplasia. Because atomic spacings between the amide moieties in ß-alethine are the same as in the differentiating agent hexamethylene-bis-acetamide and because the radioprotectors WR 2721 and WR 1065 lack only the carbonyl oxygen of the thiol form (ß-aletheine), biological activities already reported for these compounds are compared with those presented herein for ß-alethine. Although these comparisons have not been made in the same systems, the tentative conclusion is that the amide moieties of ß-alethine may be critical to its potency and lack of obvious toxicity in cell culture and animal models.

1 Early work on this project was funded by NIH Grants HL16796, AM10628, and Basic Research Support Grant BRSG SO7RR-05583-25.

2 To whom requests for reprints should be addressed, at University of New Mexico, P.O. Box 702, Basic Sciences Building 1, Albuquerque, NM 87131.

Received 2/15/94. Accepted 8/26/94.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1994 by the American Association for Cancer Research.